DepoMed acquires Nucynta (tapentadol) US rights from Janssen Pharmaceuticals for $1.05 billion

Depomed, Inc.has announced that it has entered into a definitive agreement to acquire the U.S. rights to the Nucynta franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The Nucynta franchise includes Nucynta ER (tapentadol) extended release tablets indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy severe enough to require daily, around-the-clock, long-term opioid treatment, and Nucynta (tapentadol), an immediate release version of tapentadol, for management of moderate to severe acute pain in adults. Nucynta (tapentadol) oral solution is an approved oral form of tapentadol that has not been launched.